dSMAX-3

ATP7A | 2010

What Is dSMAX-3?

dSMAX-3 is a type of CMT caused by X-linked recessive mutations in the ATP7A gene. This gene provides instructions for making a copper-transporting protein essential to the normal function of motor nerve cells. Mutations in the ATP7A gene disrupt this function, leading to impaired nerve signal transmission.

dSMAX-3 is X-linked recessive. This means the gene lives on the X chromosome, and in people with two X chromosomes (chromosomal females), a mutation in both copies of the gene is needed to cause dSMAX-3. For individuals with one X and one Y chromosome (chromosomal males), a mutation in their single copy of the gene is sufficient to cause dSMAX-3.

Clinical Features

The age of symptom onset in dSMAX-3 is variable, ranging from childhood to adulthood. As a motor neuropathy, dSMAX-3 primarily affects the most distal points, with weakness and atrophy of the feet and hands, and little to no involvement of the sensory nerves. Nerve conduction studies usually show somewhat slowed conduction velocities and reduced amplitudes, consistent with an axonal form of CMT.

dSMAX-3 symptoms may include:

  • Weakness and atrophy in the feet and lower legs
  • Foot drop
  • Reduced or absent reflexes
  • A steppage-style walking pattern
  • Foot deformities, including high arches, and hammertoes (clawed toes)
  • Progressive involvement of the hands
  • Difficulty with fine motor skills and manual dexterity
  • Additional symptoms not listed here

Disease Course

dSMAX-3 shows wide variability in severity and progression. Some individuals are mildly affected, while others develop a more severe disease. Disease progression is generally slow, and life expectancy is not reduced.

Clinical Basics

Subtype
dSMAX-3

Classification
dSMA

Neuropathy Type
Axonal

Inheritance Pattern
X-linked recessive

Genetic Context

HGNC-Approved Gene Symbol
ATP7A

Gene Full Name
Atpase Copper Transporting Alpha

Chromosome
Xq21.1

Zygosity of Responsible Variant
Hemizygous (Male) / Homozygous (Female)

Variant Mechanism
Loss of Function (LoF)

ClinVar Pathogenic Variants

View dSMAX-3 ClinVar Variants

dSMAX-3 OMIM Entry

dSMAX-3 OMIM

ATP7A OMIM Entry

ATP7A OMIM

More Info

dSMAX-3 Research Opportunity

CMT Natural History Study

Original Discovery Publication

Publication Title

Missense Mutations in the Copper Transporter Gene ATP7A Cause X-Linked Distal Hereditary Motor Neuropathy

Authors

Kennerson, M. L., Nicholson, G. A., Kaler, S. G., Kowalski, B., Mercer, J. F., Tang, J., Llanos, R. M., Chu, S., Takata, R. I., Speck-Martins, C. E., Baets, J., Almeida-Souza, L., Fischer, D., Timmerman, V., Taylor, P. E., Scherer, S. S., Ferguson, T. A., Bird, T. D., De Jonghe, P., Feely, S. M., … Garbern, J. Y.

Publication Date
March 12, 2010

Updated: July 18, 2026 | By: K. Raymond

The Dorsal Root

More From The Dorsal Root


Close-up of a doctor’s hand holding a prescription pad while a patient’s wrist is wrapped with metal chains.


When Medicine Lost Its Compass

Evidence failed not because it was wrong, but because it was weaponized. I lived the downstream effects of that failure for more than a decade. This is what happens when medicine forgets that data always ends in a human being.


Illustrated graphic showing large ‘404’ numerals with people interacting with data screens and servers, alongside text reading ‘CMT Genetic Testing Error 404: Gene Not Found’ and ‘Examining Why Less Than Half of All Who Have Charcot-Marie-Tooth Disease Are Not Able to Obtain Genetic Confirmation of Their Disease.


Error 404: Gene Not Found

CMT genetic testing often fails to identify the cause of the disease, even when comprehensive panels are used. Here, we discuss why this happens, what genetic tests can and cannot do, and why a negative result still matters.


Illustrated cover graphic showing a split landform with branching directional arrows, two people with question marks above their heads, and the title ‘SORD Deficiency: Decoding This Newly Discovered and Confusing CMT Subtype.


CMT-SORD: What Is This Unique CMT Subtype?

CMT-SORD is a newly discovered CMT subtype driven by toxic sorbitol accumulation. This article explains how "SORD" works, why this subtype is different, and how it led to the fastest-moving therapeutic program in CMT history.